Skip to main
  2. Stocks
  3. Iovance Biotherapeutics
LBIO

Buy Iovance Biotherapeutics (LBIO) Stock

See LBIO stock price and Buy/Sell Iovance Biotherapeutics. Discuss news and analysts' price predictions with the investor community.
Start investing

Invest in LBIO

Order type
Invest in
Amount
Market price$8.20
Estimated quantity0.00
Sign up to buy
LBIO

Iovance Biotherapeutics (LBIO)

—

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Iovance Biotherapeutics (LBIO)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Ro...Read more
Market Cap
$1.3B
1 Year High
$18.73
Volume
50
1 Year Low
$5.42
Price to Earnings Ratio
—
Open
$8
Dividend Rate
—
High
$8.49
Dividend Yield
—
Low
$7.88

Community

People who own or watch LBIO stock

Iovance Biotherapeutics Price Targets

What analysts think LBIO stock price will be.
$8.20
$23.58
187.6% Upside
$5$25

Iovance Biotherapeutics Stock Rating

What analysts recommend for LBIO stock, on a scale from 1(buy) to 5(sell).
Buy
67% Strong Buy
13% Buy
20% Hold
0% Sell
0% Strong Sell

Iovance Biotherapeutics Stock Earnings

The value each LBIO share was expected to gain vs. the value that each LBIO share actually gained.
Expected
Actual

Frequently Asked Questions (FAQ)

As of Feb 06, 2023, the market cap for LBIO stock is $1.3B

The 52-week high for LBIO stock is $18.73. The current LBIO stock price $8.2 is 56.22% below its 52-week high

The 52-week low for LBIO stock is $5.42. The current LBIO stock price $8.2 has increased 33.90% from its 52-week low

No, the LBIO stock does not pay dividends to its shareholders

The target price for LBIO stock is $23.58 based on the average of what a group of analyst think LBIO stock could be worth at a future date. This is not a prediction by Public.com

How to buy LBIO stock on Public

1

Sign up for a brokerage account on Public

It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

2

Add funds to your Public account

There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

3

Choose how much you'd like to invest in LBIO stock

Navigate to the Explore page. Then, type LBIO into the search bar. When you see LBIO stock appear in the results, tap it to open up the purchase screen.

4

Manage your investments in one place

You can find your newly purchased LBIO stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets.

Buy Iovance Biotherapeutics (LBIO) Stock

See LBIO stock price and Buy/Sell Iovance Biotherapeutics. Discuss news and analysts' price predictions with the investor community.
Start investing

Invest in LBIO

Order type
Invest in
Amount
Market price$8.20
Estimated quantity0.00
Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Products
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.
Open to the Public Investing, Inc. Customer Relationship Summary

© Copyright 2023 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Additional information can be found here

Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). This content is not investment advice. These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification by the SEC or as stated in the offering materials relating to an investment opportunity, as applicable. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures, Apex Crypto.

Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries. Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically during the Regular Trading Hours. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

View Full Disclosures